Replies to post #70148 on Biotech Values

[DewDiligence]

>Do you know if the Tykerb+Femara trial was in a second-line setting? I just want to make sure I'm comparing apples to apples when I look at the 9.8 months PFS versus 8.2.<

The comparison is not apples to apples.

The Femara ± Tykerb trial contained a blend of first-line Stage-IV metastatic patients and patients who relapsed following adjuvant or neo-adjuvant therapy at least one year earlier. The trial description is at:

http://clinicaltrials.gov/ct2/show/NCT00073528

Note that only about 20% of the patients in the trial were HER2+.